AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Analysis of nearly 68,000 patients finds biosimilar adoption increased following formulary changes; however, more than 1 in 7 patients switch back to HumiraBELLEVUE, Wash., June 29, 2026 (GLOBE ...

Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...

I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it again the next time June’s macro noise hands me a discount. While short-term traders chase ...

Apogee Therapeutics, which is developing a promising atopic dermatitis drug, saw its stock close nearly 47% higher on Monday.

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a ...

AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in ​more than five ...

AbbVie will add Apogee’s IL-23 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug ...

The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a ...

While agents like AbbVie's Humira have transformed the treatment landscape, not all patients benefit equally from the drug.

Income investors keep coming back to the same playbook in choppy markets: own businesses that have raised their payouts every ...